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2 
How regulatory T cells (Tregs) control lymphocyte homeostasis is not fully 1 
understood. Here we identify two Treg populations with differing degrees of 2 
self-reactivity and distinct regulatory functions. Triplehigh (GITRhigh, PD1high, 3 
CD25high) Tregs are highly self-reactive and control lympho-proliferation in 4 
peripheral lymph nodes (LNs). Triplelow (GITRlow, PD1low, CD25low) Tregs are 5 
less self-reactive and limit development of colitis by promoting conversion 6 
of CD4 Tconvs into induced Tregs (iTregs). Although FoxP3KO (scurfy) mice 7 
lack Tregs, they contain Triplehigh-like and Triplelow-like CD4 T cells with 8 
distinct pathological properties. Scurfy Triplehigh T cells infiltrate the skin 9 
while scurfy Triplelow cells induce colitis and wasting disease. These 10 
findings indicate that TCR affinity for self-antigens drives the differentiation 11 
of Tregs into distinct subsets with non-overlapping regulatory activities. 12 
13 
The importance of CD4+ regulatory T cells (Tregs) in maintaining lymphocyte 14 
homeostasis is best appreciated in mice and humans lacking these cells. FoxP3KO 15 
(scurfy) mice1,2,3 and patients with immunodysregulation polyendocrinopathy 16 
enteropathy X-linked (IPEX) syndrome4 suffer from excessive lymphocyte 17 
activation, lymphocytic infiltration into peripheral organs and colitis, leading to 18 
death at an early age. In healthy individuals, Tregs control homeostatic 19 
proliferation of conventional T and B cells and prevent colitis5,6,7. 20 
Tregs are comprised of thymic Tregs (tTregs) and peripherally-induced Tregs 21 
(pTregs or iTregs), which originate from different precursor cells and develop in 22 
different locations. tTregs develop in the thymus and their development requires 23 
TCR stimulation with agonist peptide-MHCII antigens.8,9,10 In contrast, iTregs are 24 
generated in the periphery from naïve, mature CD4+ conventional T cells (Tconv) 25 
3 
during T cell activation in the presence of TGFβ.11 Both populations are 1 
suppresive and their functional properties have been examined. Several studies 2 
suggest that tTregs are required to control immune homeostasis and 3 
autoimmunity.5,12,13 On the other hand, iTregs have spezialized functions 4 
dependening on the type of inflammation, and have a primary role in controlling 5 
mucosal immunity and fetal tolerance.5,12,13,14  A recent study indicated that tTregs 6 
by themselves are not sufficient to suppress chronic inflammation and 7 
autoimmunity in the absence of iTregs.158
Tregs have also been characterized for their expression of surface markers 9 
and localization in different tissues.16,17,18 Based on their expression of CD44 and 10 
the lymph node homing receptor, CD62L, Tregs can be broadly divided into 11 
CD44loCD62L+ central Tregs (cTregs) and CD44hiCD62Llo/- effector Tregs 12 
(eTregs).16 cTregs are quiescent, primarily reside in secondary lymphoid tissues, 13 
express high levels of CD25 and are IL-2 dependent. In contrast, eTregs, the 14 
dominant Treg population in nonlymphoid tissues, are CD25low, highly proliferative, 15 
but prone to apoptosis. It’s been suggested that eTreg maintenance is driven by 16 
TCR and co-stimulatory signals, but not IL-2.16 17 
Several studies demonstrated the importance of TCR stimulation to activate 18 
cTregs in order to generate suppressive eTregs.8,9 Furthermore, two very recent 19 
studies provided direct evidence that TCR expression is indispensable for Treg 20 
survival and suppressive function.19,20 The Treg repertoire contains self-21 
reactive8,21,22 as well as foreign antigen reactive23 TCRs. Considering self-reactive 22 
Tregs, their TCR affinity for self-antigens has not yet been fully characterized. 23 
While it’s generally accepted that Tregs and naïve CD4+ Tconvs have non-24 
overlapping TCR repertoires, a small percentage of TCRs are found within both T 25 
4 
cell populations.24,25 Furthermore, the TCR repertories of tTreg and iTregs were 1 
shown to be distinct.26,27 While the tTreg TCR repertoire is biased toward self-2 
recognition, TCRs expressed in iTregs can recognize foreign antigens with high 3 
affinity.24,26 In line with these findings, it’s been shown that activated CD4+ T cells 4 
from TCRβtg scurfy mice preferentially used TCRs found in the Treg TCR 5 
repertoire of TCRβtg wild type mice.21 Despite these interesting findings, it’s still 6 
not clear how a Treg’s antigen specificity influences its’ regulatory properties.  7 
Here we report two functionally distinct subgroups of thymic Tregs with distinct 8 
TCR repertoires and differing TCR affinities for self-antigens. Triplelow (GITRlow, 9 
PD1low, CD25low) Tregs express TCRs whose affinities for self-antigens are close 10 
to the threshold for negative selection, while Triplehigh (GITRhigh, PD1high, CD25high) 11 
Tregs express highly self-reactive TCRs, with affinities well above the negative 12 
selection threshold. Functionally, Triplehigh but not Triplelow Tregs control the 13 
extensive lymphoproliferation in mice acutely depleted of Tregs. Conversely, 14 
Triplelow but not Triplehigh Tregs control colitis by facilitating conversion of CD4 15 
Tconv into induced Tregs (iTregs). Finally, FoxP3KO (scurfy) mice contain 16 
Triplehigh- like and Triplelow- like CD4 T cells with distinct pathological properties. 17 
Triplehigh scurfy T cells infiltrate the skin while scurfy Triplelow T cells cause colitis 18 
and wasting disease. Our results provide evidence that the degree of thymocyte 19 
self-reactivity drives the generation of distinct Treg subtypes, which control 20 







 GITR, PD1 and CD25 expression define Treg subsets 2 
FoxP3+ regulatory T cells express a continuum of GITR and PD1 (Fig 1a).  As 3 
GITRhigh / PD1high Tregs express higher levels of CD25 compared to GITRlow / 4 
PD1low Tregs (Fig 1a), we refer to these populations as Triplehigh  (GITRhigh, 5 
PD1high, CD25high) and Triplelow (GITRlow, PD1low, CD25low) Tregs, respectively. 6 
To compare these Treg populations to previously described Treg subsets16,17,18, 7 
we examined their expression of various homing and chemokine receptors (Fig 8 
1b). Based on their expression of these proteins, Triplehigh and Triplelow Tregs are 9 
distinct from each other and distinct from central and effector Tregs (Fig S1- 10 
table;16,17,18). This analysis also shows that central and effector Tregs are 11 
contained within the Tripleintermediate gate (Fig S2). 12 
Triplehigh and Triplelow Tregs originate in the thymus 13 
Although Triplehigh and Triplelow Tregs are present in the thymus (Fig 2a), they 14 
could represent Tregs recirculating from the periphery as opposed to de novo 15 
generated thymic Tregs.28,29 To resolve this, we examined thymic Tregs in mice 16 
expressing FoxP3-RFP and Rag-GFP reporters (Fig 2b). RFP+GFP+ CD4 SP 17 
thymocytes are de novo generated thymic Tregs since they are still Rag-GFP+, 18 
while RFP+GFP- CD4 SP cells in the thymus are recirculating Tregs from the 19 
periphery.29 The frequency of de novo generated (RFP+GFP+) Triplehigh and 20 
Triplelow Tregs in the thymus is similar to what’s observed among LN Tregs. The 21 
fact that both Triplehigh and Triplelow Tregs develop in the thymus argues against 22 
the idea that either population are induced Tregs (iTregs). To address the 23 
possibility that Triplehigh and Triplelow Tregs might be induced by foreign antigens 24 
or inflammation, we examined Tregs in germ-free (GF) and antigen-free (AF) 25 
6 
mice. AF mice are offspring of GF mice that were weaned onto and raised on the 1 
elemental diet of glucose and amino acids.30 As these animals lack a microbiome 2 
and are not exposed to dietary antigens, they contain exclusively self-antigens. 3 
GF and AF mice contain similar frequencies of LN Tregs compared to standard 4 
SPF animals (Fig 2c, top row). Importantly, SPF, GF and AF mice contain similar 5 
frequencies of Triplehigh and Triplelow Tregs (Fig 2c, bottom row), which also 6 
express similar levels of NRP1 and Helios (Fig S3). These data rule out the idea 7 
that the Triplehigh and Triplelow phenotypes are a response to inflammation. 8 
Furthermore, these results strongly suggest that Triplehigh and Triplelow Tregs are 9 
generated through recognition of self-antigens.  10 
Triplehigh and Triplelow Tregs express distinct TCR repertoires 11 
To directly compare the TCR repertoires of Triplelow and Triplehigh Tregs to CD4 12 
Tconvs, all three populations expressing the Vα2 family (Fig 3a), were sorted from 13 
a Rag+, single TCR β chain strain (Yae62, Vβ8.2, TCRα+/KO, FoxP3GFP-KI; Fig S4) 14 
and subjected to deep sequencing. The 500 most frequent clonotypes in each 15 
group were analyzed for their similarity (Fig 3 b-d) and diversity (Fig 3e,f). 16 
Morisita-Horn analysis shows that the CD4 Tconv sequences from three 17 
independent groups of mice (see Methods) are similar to each other but 18 
significantly different from Triplelow and Triplehigh Treg sequences obtained from 19 
the same mice (Fig 3b). Triplelow sequences isolated from different groups of mice 20 
are similar to each other as well, but different from CD4 Tconv and Triplehigh TCRs 21 
(Fig 3c). Interestingly, Triplehigh TCR sequences are not only different from CD4 22 
Tconv and Triplelow sequences, but they are also variable between different 23 
groups of mice (Fig 3d). Despite their significant sequence differences, the TCR 24 
repertoires of CD4 Tconvs and Triplelows are similarly diverse (Fig 3 e,f). The 25 
 7 
repertoire of Triplehigh Treg TCRs may be less diverse than the CD4 Tconv and 1 
Triplelow repertoires, at least according to Shannon Entropy analysis. Taken 2 
together, deep sequencing analyses showed that Triplehigh Tregs, Triplelow Tregs 3 
and CD4 Tconvs have clearly distinct TCR repertoires, implying that TCR 4 
specificity is important in selecting these Treg subtypes.  5 
Triplehigh Tregs are more self-reactive than Triplelow Tregs 6 
Up to this point, our findings suggested that Triplehigh and Triplelow Tregs are 7 
distinct populations (Fig 1, 3) selected on self-antigens (Fig 2c). To directly test 8 
whether Triplehigh and Triplelow Tregs differ in their degree of self-reactivity, we 9 
examined CD5 and Nur77 expression in each subset (Fig 4a). The expression of 10 
these markers reflects T cell activation and correlates with TCR affinity for its’ 11 
pMHC ligand.31,32 The higher expression of Nur77 and CD5 by Triplehigh Tregs, 12 
compared to Triplelow Tregs (Fig. 4a) argues that Triplehigh Tregs are more self-13 
reactive than their Triplelow counterparts. To test this idea, we used in vivo BrdU 14 
labeling and observed that Triplehigh Tregs proliferate more frequently in vivo 15 
compared to Triplelow Tregs and CD4 Tconvs (Fig 4b). Furthermore, culturing 16 
unsorted CD4 T cells on syngeneic bone marrow DCs, Triplehigh Tregs proliferate 17 
more extensively than Triplelow Tregs and CD4 Tconvs (Fig 4c); this proliferation 18 
requires expression of MHC II self-antigens on antigen presenting cells (APCs). 19 
To examine the influence of antigen affinity on the generation of CD4SP 20 
thymocytes with a Triplehigh or Triplelow phenotype (Fig 4d), B3K508TCRtg RagKO 21 
thymocytes were cultured on syngeneic BmDCs in the presence of TGFβ and IL-2. 22 
Addition of P-1A peptide (threshold negative selector) induced development of 23 
Triplelow CD4 SP thymocytes, while the P2A peptide (intermediate affinity negative 24 
selector) induced Tripleintermediate CD4SP thymocytes; finally, 3K-peptide (high 25 
8 
affinity negative selector) induced only Triplehigh CD4SP thymocytes. FoxP3+ 1 
Tregs were also generated in these cultures, but only in the presence of negative 2 
selecting peptides  (Fig 4d, middle row, Fig S5a). Culturing B3K508 RagKO 3 
thymocytes with the negative selecting ligands, P-1A (threshold negative selector), 4 
P2A (intermediate affinity negative selector) and 3K (high affinity negative 5 
selector) generated FoxP3+ Tregs expressing increasing amounts of PD1 (Fig 4d), 6 
CD25 and Helios (Fig S5b). Taken together, the data indicate that threshold-, 7 
intermediate- and high- affinity negative selecting antigens induce Triplelow, 8 
Tripleintermediate and Triplehigh Tregs, respectively (Fig 4d, bottom row; Fig S5b). 9 
That the threshold negative selector induces weaker TCR signals is supported by 10 
its decreased ability to induce pCD3ζ, pcJun and pERK (Fig S5c, d). These in vitro 11 
results were confirmed using bone marrow chimeras, where OT-II thymocytes 12 
developed in a RIP-OVA host expressing the cognate antigen, ovalbumin (Fig 4e). 13 
These chimeric mice contain Triplehigh (and intermediate) but not Triplelow Tregs in the 14 
thymus. Taken together, these data imply that Triplehigh and Triplelow Tregs are 15 
likely generated by exposure to negatively selecting antigens; moreover, the 16 
resulting Treg phenotype is most likely determined by the affinity of its’ TCR for 17 
self-antigen.   18 
Triplehigh Tregs suppress lymphoproliferation 19 
To compare the regulatory properties of these two populations, FoxP3DTR mice 20 
received sorted Triplehigh or Triplelow Tregs from B6 mice (Fig S6a), which are 21 
unaffected by diphtheria toxin (DTx). Three days later, endogenous Tregs from the 22 
FoxP3DTR host were depleted by injecting DTx every other day. LN lymphocytes 23 
then were examined by flow cytometry 11 days following the onset of Treg 24 
depletion. (Fig 5a). Triplehigh Tregs control the extensive proliferation of Tcells and 25 
9 
B cells in peripheral LNs of mice depleted of their endogenous Tregs (Fig 5b), 1 
while Triplelow Tregs function poorly in this respect. As expected, Triplehigh Tregs 2 
limit the activation of CD4 Tconvs (Fig 5c).  3 
Triplelow Tregs suppress induction of colitis 4 
To examine whether any of these Treg subsets control colitis, CD3KO mice were 5 
injected with sorted naïve CD4 Tconvs (Fig 6a), a treatment, which results in 6 
colitis (Fig 6d, upper left panel) and weight loss (Fig 6b, solid blue line) as 7 
previously described7. Co-transfer of Triplelow (Fig 6b, solid brown line; Fig 6d, 8 
upper middle panel) but not Triplehigh (Fig 6b, upper panel, solid red line; Fig 6d, 9 
upper right panel) Tregs prevented weight loss and limited lymphocyte infiltration 10 
of the colonic mucosa.  Analysis of LN cells from these mice indicated that co-11 
transferred Triplelow Tregs facilitated the conversion of some CD4 Tconv into 12 
induced Tregs (iTregs) (Fig 6e,f). Mice receiving Triplelow Tregs had the highest 13 
percentage of iTregs (Fig 6e,f), very limited infiltration of the colonic mucosa (Fig 14 
6d, upper middle panel) and maintained their weight (Fig 6b).  15 
To test whether iTregs were required to control colitis15, CD4 Tconv cells 16 
isolated from FoxP3DTR mice were transferred into CD3KO mice (Fig 6a). These 17 
animals were additionally treated with DTx every third day to deplete any iTregs 18 
developing from transferred FoxP3DTR CD4 Tconvs. iTreg depletion accelerated 19 
weight loss and development of colitis (compare solid blue (Fig 6b) and dashed 20 
blue lines in Fig 6c). Co-transferred B6 Triplelow Tregs (unaffected by DTx) were 21 
unable to control the development of colitis when iTregs were depleted (compare 22 
solid brown (Fig 6b) and dashed brown lines in Fig 6c; compare upper middle and 23 
lower middle panels in Fig 6d). The data support the idea that Triplelow Tregs 24 
 10 
facilitate conversion of some CD4 Tconv into FoxP3+ iTregs, which in aggregate 1 
limit development of colitis.  2 
Taken together, the data (Fig 5,6) argue for two populations of Tregs: Triplehighs, 3 
which control lymphoproliferation in peripheral LNs and Triplelows, which limit the 4 
development of colitis (at least in a lymphopenic setting). It should be noted that 5 
the phenotypes of Triplehighs are stable over the 11d time course of the experiment 6 
in Fig 5 while Triplelows are stable over the 6 week time course of the experiment 7 
in Fig 6. (see also Fig S6b). As Triplelows don’t suppress lympho-proliferation and 8 
Triplehighs don’t suppress colitis, there is no evidence for a significant degree of 9 
trans-differentiation between the two subsets during the time frame of these 10 
experiments. 11 
Scurfy Triplehigh and Triplelow CD4 T cells induce different pathologies 12 
While FoxP3KO (scurfy) mice cannot develop Tregs due to the lack of functional 13 
FoxP3, they do carry out negative selection.21 For this reason, we wondered 14 
whether FoxP3KO (scurfy) mice contain Triplehigh- like and Triplelow- like CD4 T 15 
cells despite their lack of a functional FoxP3 molecule. Flow cytometric analysis 16 
shows that these mice contain GITRhigh, PD1high, CD25high (scurfy Triplehigh) and 17 
GITRlow, PD1low, CD25low (scurfy Triplelow) CD4 T cells. Scurfy Triplehigh T cells 18 
resembled B6 Triplehigh Tregs in terms of PD1, GITR, CD25, Helios, CD5 and 19 
CD62L expression (Fig 7a). Given their lack of FoxP3 expression and suppressive 20 
capacity, scurfy Triplehighs may be similar to previously reported Treg 21 
“wannabes”.21,33,34 Scurfy Triplelow T cells, on the other hand resembled CD4 22 
Tconv cells with respect to their expression of these markers (Fig 7a).  23 
To investigate their pathological activities, scurfy Triplelow and scurfy Triplehigh 24 
CD4 T cells were sorted (Fig S7a) and separately transferred into T cell deficient, 25 
11 
CD3KO hosts (Fig 7b). Transferred scurfy Triplelow T cells promoted weight loss 1 
and colitis (Fig 7c,f). Moreover, they accumulate in mesenteric LNs (Fig 7d,e) 2 
where ~35% of these cells express α4β7, an integrin that enables homing to the 3 
gut35 (Fig S7b). In contrast, transferred scurfy Triplehighs do not cause weight loss 4 
(Fig 7c) and preferentially accumulate in peripheral but not mesenteric LNs (Fig 5 
7d,e).  Moreover, scurfy Triplehigh T cells induce massive inflammation in the skin 6 
but only minimal inflammation in the colon (Fig 7f). Taken together, these results 7 
indicate that the absence of normal Tregs is not the sole cause of scurfy disease; 8 
the activity of dysregulated (Treg-like) scurfy Triplehighs accounts for some of the 9 
pathology observed in these mice. 10 
11 
Discussion 12 
We examined the functionality of Treg subsets with distinct TCR repertoires 13 
and differing affinities for self-antigens. Our data suggest that Triplehigh and 14 
Triplelow Tregs are generated as an offshoot of negative selection. The high affinity 15 
self-reactive TCRs expressed by Triplehigh Tregs likely drives their selection in the 16 
thymus as well as their proliferation and suppressive activity in peripheral LNs.36 17 
On the other hand, thymic precursors expressing lower affinity self-reactive TCRs 18 
plausibly differentiate into Triplelow Tregs, which facilitate conversion of CD4 19 
Tconvs into iTregs. We also demonstrate that FoxP3KO (scurfy) mice contain 20 
Triplehigh- and Triplelow- like CD4 T cells, which are presumably derived from 21 
negative selection21 and have distinctive pathological activities: scurfy Triplehigh T 22 
cells preferentially migrate to peripheral LNs and elicit skin pathology (scurfy skin) 23 
while scurfy Triplelow cells are found in the mesenteric LNs and cause colitis.  24 
Triplehigh and Triplelow Tregs are distinct from central and effector Treg subsets. 25 
12 
With respect to CD44, CD62L and ICOS expression, Triplehigh Tregs resemble 1 
eTregs and Triplelow Tregs resemble cTregs; however, expression of CD25, CCR7, 2 
CD103, Helios and NRP1 indicates that Triplehighs and Triplelows are distinct from 3 
these previously described subsets.16 4 
Thymic Triplelow Tregs might be generated in the thymus or alternatively, are 5 
iTregs generated in the periphery, which recirculate back to the thymus. This was 6 
clarified using FoxP3-RFP / Rag-GFP dual reporter mice, which clearly show that7 
Triplehigh and Triplelow Tregs are present among de novo generated, Rag-GFP+, 8 
thymic Tregs. To address whether Triplehigh and/or Triplelow phenotypes represent 9 
an activation state induced by foreign antigens or inflammation, we examined 10 
Tregs in germ free (GF) and (foreign) antigen-free (AF) mice. GF and AF mice 11 
contain similar frequencies of Triplehigh and Triplelow Tregs as found in SPF mice 12 
on a normal diet. Since AF mice contain virtually no foreign antigens (they lack a 13 
microbiome and are fed an elemental diet), the differentiation and activation of 14 
Triplehigh and Triplelow Tregs has to be driven by self-antigens. Taken together, 15 
these data demonstrate that Triplehigh and Triplelow Tregs are generated in a 16 
programmed fashion, based on their reactivity to self-antigens. 17 
Several reports show that Tregs and CD4 Tconvs cells are differently selected 18 
and have dissimilar TCR repertoires.24,25 A comparison of the TCR repertoires 19 
expressed in thymic and peripheral (induced) Tregs is difficult due to the absence 20 
of specific markers for cell sorting.8,9,14,37,38 However, analysis of peripheral 21 
(assumed to be thymus-derived) and colonic (assumed to be peripherally induced) 22 
Tregs revealed different TCR repertories expressed in these two populations.26 23 
Deep sequencing of Triplehigh and Triplelow Tregs as well as CD4 Tconvs indicates 24 
13 
that each of these TCR repertoires is distinct; this is expected if TCR specificity is 1 
linked to Treg differentiation. The decreased TCR diversity among Triplehigh Tregs 2 
may be due oligoclonal expansion; this is consistent with their increased 3 
proliferation in vivo. It should be pointed out that given their origin, the TCR 4 
repertoire expressed on iTregs must be contained within the CD4 Tconv repertoire. 5 
That Triplelows and CD4 Tconvs express distinct repertoires argues that Triplelows 6 
and iTregs are discrete populations.  7 
Based on CD5 and Nur77-GFP reporter expression,31,32 the affinity hierarchy 8 
for self-reactivity is likely Triplehigh Tregs  > Triplelow Tregs > CD4 Tconvs. The 9 
increased proliferation of Triplehigh Tregs in vivo and in vitro also supports this idea. 10 
Exposing MHC II restricted TCR transgenic thymocytes to threshold- (weak 11 
deleting), intermediate- (moderate deleting) or high- affinity (strong deleting) 12 
antigens generate Triplelow, Tripleintermediate or Triplehigh Tregs, respectively. These 13 
data show that the idea that thymocyte affinity for self-antigen determines its cell 14 
fate also applies to Treg development.  15 
Whether different Treg populations suppress different aspects of autoimmunity 16 
is not fully known.15 Acute Treg ablation in FoxP3DTR mice leads to the activation 17 
of T cells specific for “available-antigens” including genome encoded self, 18 
environmental and food antigens. This is supported by the observation that 19 
(foreign reactive) TCRtg T cells do not undergo activation upon Treg ablation.39 20 
We show that the massive expansion of Tconvs and B cells in Treg ablated mice 21 
is controlled by transferring as few as 2.5x105 Triplehigh, but not Triplelow Tregs. 22 
Within 48h following Treg depletion, DCs upregulate surface MHCII, CD8039 and 23 
undergo a 2-12 fold  expansion.40 Triplehigh Tregs may suppress 24 
14 
lymphoproliferation in peripheral LNs by either modifying DCs towards a 1 
tolerogenic phenotype41 or by directly interacting with T cells.42 2 
Experimental colitis induced by transfer of CD4 Tconvs into T cell deficient 3 
hosts is a slow, progressive disease mediated by microbiota-specific CD4+ T cells 4 
and characterized by a massive cell infiltration into the colon and weight loss 5 
within four to six weeks.7,43 A number of reports show that co-transfer of Tregs, in 6 
particular microbiota-specific Tregs prevents the onset or even cures mice from 7 
colitis.43, 44 iTregs are essential for maintaining immune homeostasis, especially at 8 
mucosal interfaces; additionally iTregs contribute to fetal tolerance.5,12,13 In the gut, 9 
naïve CD4+ T cells are converted into iTregs following TCR stimulation in the 10 
presence of TGFβ and IL-2; other compounds such as retinoic acid (RA) or short-11 
chain-fatty-acids from microbiota mediate conversion as well.7 In addition, IL-10 is 12 
a key player in maintaining lymphocyte homeostasis in the gut as IL-10 deficient 13 
mice suffer from spontaneous colitis.7 14 
Our results clearly show that Triplelow but not Triplehigh Tregs suppress colitis 15 
induction. Triplelow Tregs by themselves do not control colitis induction, but 16 
function by promoting the generation of iTregs from CD4 Tconvs. Mice which 17 
received Triplelow Tregs, but whose recently generated iTregs were depleted with 18 
DTx develop fulminant colitis. To our knowledge, there is no study, showing that a 19 
particular Treg cell population can induce the conversion of CD4 Tconvs in iTregs 20 
in vivo. One recent study indicates that M2a macrophages promote a supportive 21 
environment for iTregs and directly contribute to immunological homeostasis in the 22 
gut.45 Nevertheless, how Triplelow Tregs facilitate the generation of iTregs is still an 23 
open question. 24 
15 
Treg-like “wannabe” CD4 T cells accumulate in scurfy mice.33,34 These Treg-1 
like scurfy T cells are phenotypically similar to bona fide Tregs and even express 2 
similar TCRs.21 Interestingly, transfer of Tconv-like CD4 T cells from scurfy mice 3 
resulted in colitis, but not the other features of scurfy disease.33  4 
It’s still not clear which scurfy T cell population promotes multi organ 5 
inflammation and how TCR affinity for self or foreign antigen is linked to the 6 
various pathologies seen in scurfy mice. Here, we show that scurfy Triplehigh T 7 
cells are similar to bona fide Triplehigh Tregs with respect to PD1, GITR, CD25 and 8 
Helios expression. Transferred scurfy Triplehighs proliferate extensively in 9 
peripheral LNs, infiltrate the skin and cause cutaneous lesions similar to those 10 
seen in scurfy mice. Interestingly, IL-2 deficient scurfy mice do not develop skin 11 
lesions, while IL-4-, IL-6-, IL-10-, Stat6- or CD103- deficient scurfy mice do.46 The 12 
authors suggested that IL-2 acts as the main mediator of skin inflammation in 13 
scurfy mice. In this context, scurfy Triplehigh cells cannot likely produce their own 14 
IL-2, since they express Helios, a repressor of IL-2 transcription.34 For this reason, 15 
the presence of IL-2 secreting, skin resident DCs might explain the accumulation 16 
of scurfy Triplehighs in the dermis.47  17 
In contrast, scurfy Triplelow cells do not initiate cutaneous lesions, but instead 18 
induce severe colitis within 4 weeks when transferred to T cell deficient recipients. 19 
It’s unclear whether scurfy Triplelow cells are the scurfy equivalent to B6 Triplelow 20 
Tregs or to B6 CD4 Tconv cells.  Nevertheless, at least a portion of scurfy Triplelow 21 
cells are likely to be microbiota specific, since germfree scurfy mice are less prone 22 
to develop colitis compared to scurfy mice housed under SPF conditions.26,36 23 
Taken together, these results indicate that scurfy disease is pleotropic. Although 24 
the absence of bona fide Tregs is the major contributor to the scurfy phenotype, 25 
16 
the presence of dysregulated Treg-like cells very likely initiates several 1 
pathological aspects of this disease. 2 
In summary, our results show that the extent of self-reactivity underlies the 3 
development of two distinct populations of regulatory T cells. The highly self-4 
reactive Triplehigh Tregs control the homeostatic proliferation of lymphocytes, while 5 
the less self-reactive Triplelow Tregs facilitate the generation of iTregs in order to 6 
maintain lymphocyte homeostasis in the colon. Scurfy mice contain dysregulated 7 





All mice (female and male) were between 5–12 weeks old and had a C57BL/6 3 
genetic background. Male FoxP3KO mice were used at 2-3 weeks of age. CD45.1 4 
congenic C57BL/6 (B6 Ly5.1), CD45.2 congenic C57BL/6 (B6), RIP-OVA mice 5 
expressing a membrane bound form of Ova under the control of the rat insulin 6 
promoter (RIP)48,49,39 OTII TCRtg mice recognizing IAb/OVA323-33950, B6.Nur77-7 
GFP31 and FoxP3KO51 were all obtained from The Jackson Laboratory (Bar 8 
Harbor, ME). 3BK506 TCRtg and 3BK508 TCRtg mice recognizing IAb/3K and 9 
Triple KO mice deficient for MHC class II, invariant chain and RagKO (referred here 10 
as MHCII KO) were provided by P. Marrack and J. Kappler (Denver, USA) and are 11 
described elsewhere52. FoxP3DTR,39 mice were kindly provided by A. Rudensky 12 
(New York, USA). FoxP3eGFP and CD3ε-/- (CD3KO) were kindly provided by T. 13 
Rolink (Basel, Switzerland) and single TCR β chain (OT-I Vβ5) transgenic mice 14 
kindly provided by D. Zehn (Lausanne, Switzerland) and are described 15 
elsewhere.53,54,55 Mice were housed under specific pathogen-free conditions and 16 
bred in our colony (University Hospital Basel) in accordance with Cantonal and 17 
Federal laws of Switzerland. Animal protocols were approved by the Cantonal 18 
Veterinary Office of Baselstadt, Switzerland. Mice expressing the YAe62 TCRβ 19 
chain56,57 and all mouse sub-lines were maintained in a pathogen-free 20 
environment in accordance with institutional guidelines in the Animal Care Facility 21 
at the University of Massachusetts Medical School. Foxp3.RFP/GFP mice on the 22 
C57BL/6 background were bred and maintained at the animal facility of the CRTD 23 
(Dresden, Germany) under specific pathogen-free conditions; animal experiments 24 
were performed in accordance with the German law on care and use of laboratory 25 
18 
animals and approved by the Regieriungspräsidium Dresden. Antigen free and 1 
germ free C57BL/6 mice30 were bred and maintained at the animal facility of the2 
Pohang University of Science and Technology. This research was approved by 3 
the Institutional Animal Care and Use Committees (IACUC) of the Pohang 4 
University of Science and Technology (2013-01-0012). Mouse care and 5 
experimental procedures were performed in accordance with all institutional 6 
guidelines for the ethical use of non-human animals in research and protocols 7 
from IACUC of the Pohang University of Science and Technology. FoxP3-RFP / 8 
Rag-GFP dual reporter mice29 on the C57BL/6 background were bred and 9 
maintained at the animal facility of the Biomedical Services Unit at the University 10 
of Birmingham and all experiments were performed in accordance with local and 11 
national Home Office regulations. 12 
Flow Cytometry and cell sorting 13 
Thymocytes and T cell were stained with LIVE/DEAD Fixable near-IR stain Kit 14 
(Life Technologies, Invitrogen) and surface antibodies against CD3 (145-2C11), 15 
CD4 (RM4-5), CD5 (53-7.3), CD8 (53.58), CD19 (ID3), CD25 (PC61), CD44 (IM7), 16 
CD45.1 (A20), CD45.2 (104), CD45R (B220, RA3-6B2), CD62L (MEL-14), CD103 17 
(2E7), CD197 (CCR7, 4B12), CD278 (ICOS, 7E.17G9), CD279 (PD1, RMP 1-30), 18 
CD357 (GITR, DAT-1/ YGITR765), NRP1 (polyclonal), TCRβ (H57-597) and α4β7 19 
(DATK32). Intracellular staining for FoxP3 (FJK-16s/ 150D), Helios (22F6), pcJun 20 
(D47G9), pCD3ζ (K25-407.69) and pERK (197G2) was performed using the 21 
FoxP3 staining kit (eBioscience). For BrdU experiments, mice were injected with 22 
1mg/d BrdU (5-bromodeoxyuridine, BD Bioscience) for 3 days and cells were then 23 
stained for incorporated BrdU using a BrdU Flow Kit (BD Bioscience) followed by 24 
staining for intracellular markers. All antibodies were purchased from BD 25 
19 
Bioscience, BioLegend, eBioscience or CellSignaling Technology. For flow 1 
cytometric analysis, a FACS CantoII (BD Bioscience) and FlowJo software 2 
(TreeStar) were used. For cell isolation, CD4+Tcells were enriched using 3 
Dynabeads® Untouched™ Mouse CD4 Cells Kit (Life Technologies, Invitrogen) 4 
from cell suspensions from different sources (peripheral LN, mesenteric LN, 5 
spleen); subpopulations of enriched CD4 cells were further sorted on a 6 
FACSAriaIII or Influx cell sorter (BD Biosciences). Cell numbers were determined 7 
using AccuCheck Counting Beads (Life Technologies, Invitrogen) according to 8 
manufacturer’s instructions. 9 
In vitro assays 10 
Bone marrow derived DCs (BmDCs) were generated from bone marrow cells 11 
of 5-7 week old B6 or B6.MHCIIKO mice. Bone marrow cells were cultured under 12 
maturation conditions for 10 days in full medium supplemented with GM-CSF 13 
(hybridoma supernatant, LUTZ-GMCSF, kindly provided by V.Horejsi). Autologous 14 
mixed lymphocyte reactions (auto-MLRs) were performed by co-culturing 1x10515 
syngeneic (B6 or MHCII KO) BmDCs with 3x105 CFSE labeled (Life Technologies, 16 
Invitrogen) magnetic bead enriched CD4 cells (Dynabeads, Invitrogen) in 96-well-17 
U-shaped plates for 5 days. For in vitro, Treg development experiments, 1x10518 
thymocytes from 3BK508tg mice were co-cultured with 1x105 B6 BmDCs in the 19 
presence of IL2 (25U/ml, hybridoma X63 supernatant) and recombinant mouse 20 
TGFβ1 (10ng/ml, R&D Systems) for 48h with or without 10-6M 3K 21 
(FEAQKAKANKAV), P2A (FEAAKAKANKAVD) or P-1A (FAAQKAKANKAVD) 22 
peptides (all obtained from Eurogentec). Re-aggregated thymic organ cultures 23 
were performed as previously described.58 In brief, RTOC were established from 24 
B3K508, MHC II KO thymocytes and thymic epithelial cells from B6 mice and 25 
20 
cultured in presence of P-1A (20 µM), P2A (2 µM) or 3K (0.2 µM) peptides for 7 1 
days before analysis. All in vitro assays were performed at 37°C in 5% CO2 using 2 
complete RPMI medium (GIBCO, Life Technologies). 3 
Generation of bone marrow chimeric mice 4 
For generating bone marrow chimeric mice, the protocol from Koehli et al.49 5 
was adapted. Recipient mice (CD45.1/2) were lethally irradiated with 900 rad 6 
(GammaCell, Best Theratronics, CA). Bone marrow cells from 5-8 week old B6 7 
mice (CD45.1) and OT-II RagKO (CD45.2) were isolated and depleted of mature T 8 
cells. A mixture of 9:1 of B6 and OT-II RagKO bone marrow cells (4x106 total cells) 9 
were injected intravenously (i.v.) into irradiated recipient mice. Mice were analyzed 10 
12-14 weeks after reconstitution and treated with antibiotics (Nopil, Mepha 11 
Pharma AG) in the drinking water until 2 weeks before analysis. The congenic 12 
markers CD45.1 and CD45.2 were used to identify T cells derived from different 13 
donor bone marrows as well as the host. 14 
In vivo suppression assays  15 
FoxP3DTR mice were injected intra-peritoneally (i.p.) with Diptheria Toxin 16 
(DTx) (Calbiochem) every other day for 10-12 days (first and second injection 17 
50µg/kg; subsequent injections 25µg/kg). In some groups, 2.5x105 sorted Tregs 18 
from pooled LNs were injected i.v. 3 days prior to first DTx injection. Mice were 19 
analyzed one day after last their DTx injection. For colitis experiments, 6-10 week 20 
old T cell deficient CD3KO mice received (i.v.) 3.2x105 sorted naïve CD4 T cells 21 
from pooled LNs of B6Ly5.1 (CD4+CD25-) or FoxP3DTR Ly5.1 (CD4+GFP-) mice. In 22 
some groups, 0.8 x105 sorted Tregs from pooled LN were co-transferred. 23 
Recipients of naïve FoxP3DTR CD4 Tcells (CD4+GFP-) were injected every third 24 
day with DTx (10µg/kg), i.p.. For adoptive transfer of scurfy CD4 T cells, 6-10 25 
21 
week old T cell deficient CD3KO were reconstituted with 5x105 sorted CD4 1 
subpopulations from pooled LNs of 2-3 week old sick (scurfy) FoxP3KO male mice. 2 
Recipient mice were weighed weekly at the same time of day and sacrificed when 3 
initial body weight droped more than 20% or at the latest six weeks after T cell 4 
transfer. The congenic markers, Ly5.1 and Ly5.2 were used to identify T cells from 5 
the different donors as well the host. Tissue samples were fixed in 4% 6 
paraformaldehyde, embedded in parafin, sectioned and stained with hematoxylin 7 
and eosin. 8 
Clonotype Analysis of GITRlow PD-1low versus GITRhigh PD-1high peripheral 9 
Tregs   10 
Naïve CD4+ (CD4+ CD25- Foxp3- ), Triplelow Treg (CD4+ CD25low Foxp3+ 11 
GITRlow PD-1low) or Triplehigh Treg (CD4+ CD25high Foxp3+ GITRhigh PD-1high) T cell 12 
populations were sorted from 3 replicate groups (2 mice per group) of single TCRβ 13 
chain transgenic (B6.YAe62βtg+ TCRα+/-) mice were sorted to 98% purity (FACS 14 
Aria, BD Biosciences).  RNA was isolated using Trizol and precipitated with 15 
RNase free glycogen (Invitrogen) following the manufactures protocol.  cDNA was 16 
prepared using oligo-dT’s (Promega) and Omniscript RT kit (Qiagen).  cDNA was 17 
amplified with 20 rounds PCR with generic Vα2 primer (5’-18 
CCCTGGGGAAGGCCCTGCTCTCCTGATA-3’) and  TCR Cα primer (5’-19 
GGTACACAGCAGGTTCTGGGTTCTGGATG-3’). 1/10th volume of the first round 20 
PCR was amplified with an additional 20 rounds of PCR using barcoded primers, 21 
for post sequence identification of originating T cell population, containing Illunima 22 
PE read primer and P5/7 regions, respectively.  The resulting 300bp fragment was 23 
gel purified (Gene Clean II, MP Biomedicals) and sequenced on a MiSeq using a 24 
single read 250bp run (Illumina).  Sequence data sets were parsed by barcode 25 
 22 
using the program fastq-multx59 and clonotypes for each population were 1 
tabulated using TCRklass60. A table of analyzed sequences and their frequencies 2 
is shown in Fig S8. All sequences will be made available online. 3 
Similarity and Diversity of TCR clonotypes 4 
The similarity of TCRs utilized within each population was quantified using the 5 
Morisita-Horn similarity index, 0 (minimal similarity) and 1 (maximal similarity).  6 
The Morisita-Horn (M-H) similarity indexes were calculated by tabulating the 7 
frequency in which the top 500 clonotypes of an individual population from one 8 
replicate sample was found in all other populations, using EstimateS Ver9.1.061 9 
software.  Statistical significance for M-H index values was assessed using a 10 
Mann-Whittney U test, GraphPad Prism version 6.04. The diversity of TCR 11 
repertoire for each population was measured using the top 500 most frequent 12 
clonotypes.  The Shannon Entropy62 value for each sample was calculated as H = 13 
−Σpilog2 pi, where pi is the frequency of the clonotype within the top 500 14 
clonotypes.  Lower H values indicate lower diversity.  Additionally, the Simpson's 15 
diversity index63 using the formula Ds = 1 − Σ[ni(ni − 1)]/[N(N − 1)], where ni is the 16 
TCR clone size of the ith clonotype and N is the total number of the top 500 17 
clonotypes sampled.  The index ranges from 0 to 1 with 1 indicating high diversity.  18 
Statistical analysis 19 
Statistical analysis were performed using Prism 6.0 (Graphpad software). If not 20 
other indicated, Students t test (unpaired, two-tailed) was used to asses statistical 21 
significiance. P-values ≤ 0.05 were considered significant (*p≤ 0.05, **p≤ 0.01, 22 
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Figure Legends 1 
 2 
Figure 1: Triplehigh and Triplelow Tregs cells are phenotypically distinct and 3 
originate in the thymus.  4 
a) CD4 LN T cells were analyzed for FoxP3, GITR, PD1 and CD25 expression by 5 
flow cytometry. Gates show frequencies of CD4+FoxP3+ cells (left panel, green 6 
gate), Triplehigh Tregs (GITRhighPD1highCD25high, second panel, red gate) and 7 
Triplelow Tregs (GITRlowPD1lowCD25low, second panel, brown gate). Bar graph (left) 8 
shows frequencies of Triplehigh and Triplelow Tregs in LNs of B6 mice (n=6 mice). 9 
Histogram (right panel) shows CD25 expression (MFI) on Triplehigh and Triplelow 10 
Tregs (n=4 mice) b and c) Expression of homing and activation markers on 11 
Triplehigh (red) and Triplelow Tregs (brown), obtained from B6 LNs and analyzed by 12 
flow cytometry b) CD44 and CD62L,CD103, CCR7 and ICOS c) Helios and NRP1 13 
(n= 4 mice). *p≤ 0.05, **p≤ 0.01, ***p≤0.001, ****p≤ 0.0001 (Student’s t test). Bar 14 


























































































































Figure 2: Triplehigh and Triplelow Tregs cells have thymic origin. 1 
a) B6 thymocytes mice were analyzed for FoxP3, GITR and PD1 expression by2 
flow cytometry. Gates show frequencies of Triplehigh (red) and Triplelow Tregs 3 
(brown). Bar graph shows mean frequency of Triplehigh and Triplelow Tregs in thymi 4 
(n=6 mice, data is taken from 3 independent experiments.) b) CD4SP FoxP3+5 
thymocytes from FoxP3RFP/Rag2GFP dual reporter mice were analyzed by flow 6 
cytometry for RagGFP expression (left histogram). Frequencies of Triplehigh and 7 
Triplelow Tregs among recirculating thymocytes RagGFP- (left contour plot) and de 8 
novo generated RagGFP+ (right contour plot) are indicated. Bar graphs depict 9 
mean frequencies of Triplehigh (red) and Triplelow (brown) Tregs among 10 
recirculating (RagGFP-) and de novo generated (RagGFP+) thymocyte 11 
populations. c) Lymph node cells from SPF, germ free (GF) and antigen free (AF) 12 
B6 mice were analyzed for CD4, FoxP3, GITR and PD1 expression by flow 13 
cytometry. Frequencies of FoxP3+ CD4 T cells are shown (top row, green gates). 14 
Bar graphs show mean frequency of FoxP3+ CD4 T cells. Frequencies of Triplehigh 15 
(red gates) and Triplelow Tregs (brown gates) are shown (bottom row). Bar graph 16 
show mean frequencies of Triplehigh (red bar) and Triplelow (brown bar) Tregs. (n=2 17 


















































































































Figure 3: Triplehigh and Triplelow Tregs express distinct TCR repertoires. 1 
Analysis TCR clonotypes in Treg subsets from Yae62 Vβ8.2, TCRα+/KO FoxP3-2 
GFPKI (single TCR β chain) mice. a) Vα2 expression among CD4 Tconvs (blue), 3 
Triplehigh Tregs (red) and Triplelow Tregs (brown). b) Morisita-Horn similarity 4 
analysis of Vα2+ TCR clonotypes from CD4 Tconvs (blue) compared to Triplelow 5 
(brown) Treg and Triplehigh (red) Treg clonotypes from three independent groups 6 
of single TCRβ chain (YAe62tg, TCRα+/KO, Rag+) mice. For the Morisita-Horn 7 
Index, values of 0 and 1 represent minimal and maximal similarity, respectively 8 
(see Methods for full description).  c) Morisita-Horn similarity analysis comparing 9 
Vα2+ TCR clonotypes from Triplelow Tregs (brown) to CD4 Tconvs (blue) and 10 
Triplehigh Treg (red) clonotypes. d) Morisita-Horn similarity analysis comparing 11 
Vα2+ TCR clonotypes from Triplehigh Tregs (red) to CD4 Tconvs (blue) and 12 
Triplelow Treg (brown) clonotypes. TCR repertoire diversity was analyzed by 13 
calculating Shannon Entropy (e) and Simpson Diversity (f) scores. For Shannon 14 
Entropy analysis, higher H values indicated higher diversity; for Simpson Diversity 15 
analysis, the index ranges from 0 to 1 with 1 indicating high diversity (see Methods 16 























































































Figure 4: Triplehigh and Triplelow Tregs have different self-reactivity. 1 
a) Triplehigh (red) and Triplelow (brown) Tregs from B6 LNs were analyzed for CD52 
(n=4 mice) and Nur77-GFP (n=2 mice) expression by flow cytometry. Bar graphs 3 
indicate mean MFI.  b) In vivo proliferation of B6 LN derived Triplehigh (red), 4 
Triplelow (brown) Tregs and Tconvs (blue). Mean percentages of proliferating 5 
(BrdU+) cells are shown (n=4 mice). c) Representative histograms show in vitro 6 
proliferation (CFSE dilution) of LN-derived Triplehigh Tregs (red) Triplelow Tregs 7 
(brown) and CD4 Tconvs (blue) from cultures of purified CD4 LN Tcells and B6 or 8 
B6.MHCIIKO BmDCs. Bar graph shows mean numbers of proliferating cells (n=6 9 
samples from 2 independent experiments). ns= not significant, *p≤ 0.05 (Student’s 10 
t test). Bar graphs indicate mean ± SEM. d) Representative flow cytometric 11 
analysis of GITR and PD1 expression on 3BK508tg CD4SP (top row) or 3BK508tg 12 
CD4SP FoxP3+ thymocytes (bottom row) 48h after stimulation with P-1A, P2A, 3K 13 
or no peptide presented on mature B6 BmDCs in the presence of IL2 and TGFβ 14 
(n=3 independent experiments). Middle row shows FoxP3 expression among 15 
CD4SP cells in these cultures as indicated e) Left panels: Flow cytometric 16 
analysis of FoxP3 expression in OT-II derived, CD4SP thymocytes, of lethally 17 
irradiated RIP-mOVA (upper panel) and B6 (lower panel) bone marrow chimeras 18 
reconstituted with bone marrow cells from Ly5.1+ B6 and Ly5.2+ OT-II, RagKO mice. 19 
Numbers indicate percentage of cells within gates. Right panel: Flow cytometric 20 
analysis of thymic OTII derived CD4SP FoxP3+ thymocytes for GITR and PD1 21 
expression in RIP-mOVA hosts. Contour plots are representative of 4 individual 22 

















































































































































Figure 5: Triplehigh but not Triplelow Tregs suppress in vivo 1 
lymphoproliferation. 2 
a) 2.5x105 sorted B6 Tregs cells, (unaffected by DTx) from pooled B6 LNs were3 
injected intravenously (i.v.) into 6-10 week old FoxP3DTR mice. Three days later, 4 
host FoxP3+ cells were depleted intra peritoneal (i.p.) injection of DTx every other 5 
day for 10 days. Proliferation of host lymphocytes in Ly5.1 FoxP3DTR mice 6 
previously injected i.v. with either no cells (black, n=10 mice), B6 Triplelow Tregs 7 
(brown, n=4 mice) B6 Triplehigh Tregs (red, n=6 mice), or total B6 Tregs (green, 8 
n=3 mice). FoxP3DTR recipients (see above) and B6 control mice (gray, n=4 mice) 9 
were treated every other day with diphtheria toxin (DTx) and analyzed at d11-13 10 
after cell transfer. Bar graphs show numbers of host-derived, live, CD4+, CD8+ and 11 
B cells in peripheral LNs. c) Flow cytometric contour plots and bar graph show the 12 
percentage of naïve endogenous CD4 Tconvs (Ly5.1+ CD44low CD62Lhigh) in mice 13 
described in b) n≥4.*p≤ 0.05, **p≤ 0.01, ***p≤0.001, (Student’s t test). Bar graphs 14 
show mean ± SEM. Data is taken from 2-4 independent experiments.  15 
16 
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Figure 6: Triplelow but not Triplehigh Tregs suppress colitis. 1 
a) To induce colitis, 6-10 week old T cell deficient CD3KO recipients received2 
3.2x105 sorted naïve CD4 Tconvs (CD4+CD25-) isolated from B6 Ly5.1+ mice (B6 3 
Tconv). In some groups, 0.8 x105 sorted, Ly5.2+ Triplehigh or Triplelow Tregs from 4 
pooled B6 LNs were co-transferred along with Tconvs. In experiments where iTreg 5 
generation was inhibited during colitis induction, 6-10 week old T cell deficient 6 
CD3KO recipients were first injected i.v. with 3.2x105 sorted, naïve CD4 Tconvs 7 
isolated from FoxP3DTR, Ly5.1+ mice (FoxP3DTR Tconv). In some groups, 0.8 x1058 
sorted B6 Triplelow Tregs cells (unaffected by DTx) were co-transferred along with 9 
FoxP3DTR Tconvs. To deplete Tconv-derived iTregs, recipients were injected i.p. 10 
every third day with DTx (10µg/kg). Mice were weighed weekly at the same time of 11 
day and were sacrificed when they lost > 20% of their initial body weight or at six 12 
weeks following adoptive transfer. b) Graph shows percentage of weight change 13 
of CD3KO mice injected with either no cells  (black, n=5), Ly5.1 B6 CD4 Tconvs 14 
(blue, n=9 mice) or Ly5.1 B6 CD4 Tconvs co-transferred with either Ly5.2 Triplelow15 
Tregs (brown, n=9 mice) or Triplehigh Tregs (red, n=6 mice). c) Graph shows 16 
percentage of weight change in CD3KO mice, which received either no cells  (black, 17 
n=5 mice), Ly5.1 FoxP3DTR CD4 Tconvs alone (dashed blue, n=3 mice) or Ly5.1 18 
FoxP3DTR CD4 Tconvs co-transferred with B6 Triplelow Tregs (dashed brown, n=3 19 
mice) and injected every third day with DTx. Statistical analysis compares 20 
difference of weight change at 6 weeks following cell transfer. *p≤ 0.05, **p≤ 0.01, 21 
***p≤0.001 (Student’s t test). d) Representative H&E staining of colon sections 22 
from CD3KO mice adoptively transferred with cell populations indicated in a-c). e) 23 
Flow cytometric analysis of Ly5.1 B6 CD4 Tconvs or Ly5.1 FoxP3DTR CD4 Tconvs 24 
six weeks after transfer from mice described in c). Contour plots show CD4/FoxP3 25 
34 
staining of transferred CD4 Tconvs isolated from mesenteric or peripheral LNs. f) 1 
Bar graphs show percentage of CD4 Tconv-derived induced Tregs (iTregs) found 2 
in mesenteric or peripheral LNs. *p≤ 0.05, **p≤ 0.01 (Student’s t test) ns = not 3 
significant. Bar graphs show mean ± SEM. Data is taken from 2-4 independent 4 
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Figure 7: Scurfy Triplehigh and scurfy Triplelow CD4 T cells induce different 1 
pathologies.  2 
a) FoxP3KO (Scurfy) mice contain Treg like cells. Left panel: Flow cytometric 3 
analysis of CD4 T cells showing scurfy Triplehigh (PD1high GITRhigh CD25high; orange 4 
gate) and scurfy Triplelow (PD1neg GITRneg CD25neg; purple gate) CD4+ T cells. 5 
Additional panels: PD1, GITR, CD25, Helios, CD5 and CD62L expression in 6 
scurfy Triplehigh (orange solid), scurfy Triplelow, (purple solid), B6 Triplehigh Tregs 7 
(dotted red) and B6 CD4 Tconv (dotted blue) cells. b) Sorted scurfy Triplehigh or 8 
scurfy Triplelow T cells were transferred to T cell deficient CD3KO hosts. Host mice 9 
were weekly monitored for weight change and development of other pathologies.  10 
c) Graph shows mean percentage of weight change ± SEM of CD3KO recipients 11 
following adoptive transfer of no (black, n=3 mice), scurfy Triplehigh (orange, n=8 12 
mice) or scurfy Triplelow (purple, n=8 mice) CD4+ T cells.  ***p≤ 0.001 (Student’s t 13 
test) ns = not significant. d) Photographs of peripheral and mesenteric LNs from 14 
CD3KO mice transferred with scurfy Triplehigh or scurfy Triplelow CD4 T cells e) 15 
Absolute number of scurfy CD4 cells ± SEM in peripheral LNs and mLNs six week 16 
after cell transfer, (orange, scurfy Triplehighs; violet, scurfy Triplelows) (n=8 mice) , 17 
*p≤ 0.05. f) Representative photographs and H&E staining of tail skin and colons 18 
sections of CD3KO recipient six weeks after adoptive cell transfer. B6 control mice 19 
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